

National Medical Products Administration (NMPA) approves deuremidevir (VV116) and simnotrelvir-ritonavir for mild to moderate COVID-19 in China.

Ke-Wei Zhu¹

¹Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

March 13, 2023

Hosted file

Manuscript.docx available at <https://authorea.com/users/586807/articles/629425-national-medical-products-administration-nmpa-approves-deuremidevir-vv116-and-simnotrelvir-ritonavir-for-mild-to-moderate-covid-19-in-china>

Hosted file

Fig. 1_.docx available at <https://authorea.com/users/586807/articles/629425-national-medical-products-administration-nmpa-approves-deuremidevir-vv116-and-simnotrelvir-ritonavir-for-mild-to-moderate-covid-19-in-china>